 - Adverse events from previous cancer therapies excluding alopecia must have recovered to grade 1 CTCAE, most recent version. Stable grade 2 AEs such as endocrine conditions are allowed, and other chronic stable AEs may be considered on a case by case basis by the Principal Investigator. 